SOUTH PLAINFIELD, New Jersey, Feb. 25, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Guido Schopen, M.D. to General Manager and Head of Medical Affairs for Europe. Dr. Schopen will be responsible for European commercial operations, reporting to Mark Rothera, Chief Commercial Officer of PTC.
"We are delighted to welcome Dr. Schopen to our team where he will play a key leadership role in building out our European commercial capabilities," stated Mr. Rothera. "PTC is expanding its commercial footprint with a near term focus on certain pre-approval activities. Our ultimate goal is to build a specialty global commercial organization to bring ataluren to Duchenne muscular dystrophy and cystic fibrosis patients as soon as possible following regulatory approvals. Dr. Schopen's medical and commercial expertise will be instrumental in achieving this goal."
Prior to joining PTC, Dr. Schopen was Vice President, Global Commercial Operations and Medical Affairs for TiGenix NV, where he oversaw both the commercialization of the first approved cell therapy product for cartilage repair in Europe (ChondroCelect®) and the clinical development strategy of the company's adult stem cell programs. Dr. Schopen has more than 20 years of experience in the industry with leadership positions in sales, marketing, business development, life-cycle management, clinical development and general management at ICI Pharma, UCB Pharma, Bayer HealthCare and Behringwerke. He received his undergraduate and medical degrees from the University of RWTH Aachen, Germany.
"I am pleased to join PTC at this exciting time in the company's evolution. Ataluren is a novel product candidate with significant potential across multiple genetic disorders," stated Dr. Schopen. "PTC's unrelenting commitment to bring this potentially disease modifying therapy to patients suffering from rare disorders is impressive and I look forward to being part of that effort."
About PTC Therapeutics, Inc.
PTC is biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and which form the basis for collaborations with leading biopharmaceutical companies. For more information on the company, please visit our website www.ptcbio.com.
PTC THERAPEUTICS, INC. FORWARD LOOKING STATEMENTS:
Any statements in this press release about future expectations, plans and prospects for PTC, the development of and potential market for PTC's product candidates, our plans to develop a global commercial organization, our clinical trials, our current and planned regulatory submissions, our earlier stage programs, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan" "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from those expressed or implied by these forward-looking statements. Such risks and uncertainties include, among others, those related to the initiation and conduct of clinical trials, availability of data from clinical trials, expectations for regulatory approvals, our scientific approach and general development progress, the availability or commercial potential of our product candidates and other factors discussed in the "Risk Factors" in the most recent Quarterly Report, which is on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent PTC's views only as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing PTC's views as of any date subsequent to the date of this press release.
SOURCE PTC Therapeutics, Inc.